Could blocking growth hormone ease severe insulin resistance?
NCT ID NCT05470504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called pegvisomant in 25 adults with severe insulin resistance caused by lipodystrophy or insulin receptor gene changes. Participants give themselves daily shots for one month and have two hospital stays for tests. The goal is to see if blocking growth hormone can improve how the body handles fat and sugar.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN RECEPTOR MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare fat disorder: daily leptin shots target blood sugar and fats
- Hope for rare fat disorder: new drug shows promise in Long-Term trial
- Hope for rare fat disorder: expanded access to metreleptin offered
- New registry tracks Real-World safety of rare disease drug metreleptin
- Hope for rare fat disorder: drug keeps working in Long-Term study